Intravenous zanamivir for patients with pneumonitis due to pandemic (H1N1) 2009 influenza virus.
We report on 2 critically ill patients with pneumonitis and acute respiratory distress syndrome due to pandemic (H1N1) 2009 influenza A virus who were treated with intravenous zanamivir and had favorable clinical outcomes. Zanamivir given intravenously may be a therapeutic option in patients with critical illness and mechanical ventilation.
Härter
Georg
G
University Hospital Ulm, Dept of Clinical Infectious Diseases and Clinical immunology, Comprehensive Infectious Diseases Center Ulm and Clinic of Internal Medicine III, Albert-Einstein-Allee 23, 89081 Ulm, Germany. georg.haerter@uniklinikulm.de
Zimmermann
Oliver
O
Maier
Ludwig
L
Schubert
Axel
A
Mertens
Thomas
T
Kern
Peter
P
Wöhrle
Jochen
J
D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D016638:Critical Illness; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype / Q000302:isolation & purification*; D007251:Influenza, Human / Q000150:complications* / Q000188:drug therapy* / Q000821:virology; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D011014:Pneumonia / Q000188:drug therapy*; D012128:Respiratory Distress Syndrome / Q000188:drug therapy; D016896:Treatment Outcome; D053243:Zanamivir / Q000008:administration & dosage / Q000627:therapeutic use*
D000998:Antiviral Agents; D053243:Zanamivir